Bradykinin receptors and their antagonists.
Bradykinin and related kinins act on two receptor types, named B1 and B2. Initially identified in classical bioassays, these receptors have been cloned and characterized in binding assays performed on plasma membranes of cells expressing the native or the transfected human kinin B1 or B2 receptor types. The two classification criteria recommended by Schild, namely the order of potency of agonists and the actual affinity of antagonists have been found to be applicable for receptor classification based not on data only from bioassays but also from other approaches (binding assays, molecular biology techniques). The order of potency for agonists was found with naturally occurring peptides (the kinins, their desArg9-metabolites) and with selective agonists (e.g., [Hyp3]bradykinin, [Aib7]bradykinin): the findings obtained with agonists could be validated with various antagonists. Critical evaluation of the initial compounds, typified by D)-Arg-[Hyp3, D-Phe7]bradykinin, has indicated that they are short-acting, partial agonists, non-selective for the bradykinin B2 receptor because they can be metabolized to desArg9-fragments that act on the kinin B1 receptor. Use of such compounds has given rise to misunderstandings, especially with regard to new receptor types (e.g., type B3), the existence of which was not confirmed by molecular cloning. A second generation of antagonists, represented by D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (HOE 140) has been found resistant to degradation, long-acting in vivo, selective and specific for the B2 receptor and potent in all species tested. HOE 140 has been used successfully in basic pharmacology, in animal physiopathologies involving kinins and their receptors and even in clinical studies. A third generation of non-peptide B2 receptor antagonists, whose prototype is FR 173657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-2-4-dichloro-3-[(2-methyl-8-quinolin yl)oxymethyl]phenyl]-N-methylamino carbonyl-methyl]acrylamide) is now emerging and may represent substantial progress since FR 173657 is a potent orally active, selective and specific antagonist of the human and other species B2 receptors. There is also progress regarding antagonists for the B1 receptor. The initial compounds, especially Lys-[Leu8]desArg9-bradykinin remain among of the most potent, specific and selective B1 antagonists which, however, show partial agonistic effects in some B1 receptor subtypes (e.g., the mouse). Progress has been made with AcLys-[D-betaNal7, Ile8]desArg9-bradykinin (R 715) and Lys-Lys-[Hyp3, Cpg5, D-Tic7,Cpg8]desArg9-bradykinin (B 9958) which are pure B1 antagonists in humans and rabbits; both peptides have shown resistance to degradation by peptidases and have little if any, residual agonistic activity on mouse and rat B1 receptors. No non-peptide antagonists are yet available for the B1 receptor.